NAOV: NanoVibronix, Inc. Stock

by  •  • Comments Off on NAOV: NanoVibronix, Inc. Stock

SIC 3842 – Orthopedic, Prosthetic, and Surgical Appliances and Supplies

Valuation
Market Cap ($M) 1.92
Enterprise Value ($M) -0.25
Book Value ($M) 2.84
Book Value / Share 0.76
Price / Book 0.68
NCAV ($M) 2.53
NCAV / Share 0.67
Price / NCAV 0.76

Profitability (mra)
Return on Invested Capital (ROIC) -0.95
Return on Assets (ROA) -0.38
Return on Equity (ROE) -0.60

Liquidity (mrq)
Quick Ratio 1.16
Current Ratio 2.11

Balance Sheet (mrq) ($M)
Current Assets 5.39
Assets 5.70
Liabilities 2.85
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G Armistice Capital, Llc 9.99

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-04-26 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPO
2024-04-09 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPO
2024-04-08 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-10-31 7,918 116,234 6.81
2024-10-30 35,594 301,457 11.81
2024-10-29 2,004 27,738 7.22
2024-10-28 1,428 23,317 6.12

(click for more detail)

Similar Companies
MGRM – Monogram Technologies Inc. MODD – Modular Medical, Inc.
MOVE – Movano Inc. NDRA – ENDRA Life Sciences Inc.
NEPH – Nephros, Inc.


Financial data and stock pages provided by
Fintel.io